Affectis Pharmaceuticals
Merck Serono signs neurodegenerative collaboration
June 9, 2011Research and Development Affectis Pharmaceuticals, Merck Serono
Merck Serono has struck a deal with biotech firm Affectis Pharmaceuticals to develop oral neurodegeneration compounds. The companies will commercialise …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
